Aim: To report the health resource use and estimate the direct medical costs among patients with diabetes mellitus (DM) in the year of mortality and the year preceding the year of mortality.
| INTRODUCTION
As a result of an ageing population, and environmental and lifestyle changes, the global prevalence of diabetes mellitus (DM) in adults was 8.8% in 2015, and has been predicted to increase to 10.4% in 2040. 1 The mean healthcare expenditure for each adult living with DM was US$1,583 in 2014, projecting an annual healthcare expenditure attributable to DM ranging between US$612 and US$1,099 bn worldwide. patients with DM from diagnosis to death. 3 Results from the UK Prospective Diabetes Study (UKPDS) 4 reported that patients with diabetes-related complications incurred more annual direct medical costs than those without. Another study based on multiple data sources in the United States reported the total number of deaths attributable to DM, and estimated the indirect cost attributable to early mortality. 5 The largest direct medical cost component was hospital inpatient care, followed by outpatient care and allied healthcare.
Premature mortality attributed to DM equated to US$18.5 bn in 2012. 5 Among 246 000 deaths in 2012 attributable to DM,~55%
and 28%, respectively, had renal failure and cerebrovascular disease recorded as the primary causes of death, suggesting that high direct medical costs in the mortality year may result from healthcare attributable to diabetes-related complications.
With the number of coexisting morbidities or complications gradually increasing during the survival years leading to morbidity compression and a drastic rise in healthcare resource use in the year of death, 6 
| Patient covariates
The covariates of the patients with DM included gender, age group at time of death, ethnicity, type of diabetes, presence of comorbidities, presence of diabetes-related complications, and primary cause of death.
Age at death was categorized into four groups: <65 years, 65 to 74 years, 75 to 84 years and ≥85 years. Ethnicity was divided into
Chinese and non-Chinese. Type of diabetes was identified by ICPC-2 codes T89 for insulin-dependent diabetes (Type 1 diabetes) and T90
for non-insulin-dependent diabetes (Type 2 diabetes). The level of comorbidities was measured using the Charlson comorbidity index (CCI). 10 The comorbidities for DM with and without chronic complications were excluded from the CCI calculation to avoid doublecounting. Presence of each comorbidity was scored and a final score was calculated by summing all the points. The CCI was categorized into four score groups: 0, 1, 2 and ≥3.
The association between annual direct medical cost and the presence of nine diabetic complications (acute myocardial infarction, other ischaemic heart disease, congestive heart failure, stroke, peripheral vascular disease, diabetic retinopathy, diabetic nephropathy, endstage renal disease, and diabetic foot ulcer) was tested. Other diabetes-related complications (amputation, lower limb ulcer, blindness, diabetic neuropathy and sight-threatening diabetic retinopathy) with low observation counts (<2%) were not controlled for in the regression analysis.
Because of the limited number of patients in some groups for primary cause of death, this was divided into a total of seven groups:
infectious and parasitic diseases; neoplasms; diseases of the circulatory system; diseases of the respiratory system; diseases of the digestive system; diseases of the genitourinary system; and others.
| Statistical analysis
The annual direct medical costs, their 95% confidence intervals (CIs), and the proportion of the cost of hospitalization of patients with DM at 48 to 60 months before mortality, 36 to 48 months before mortality, 24 to 36 months before mortality, 12 to 24 months before mortality, and the mortality year were calculated.
Furthermore, healthcare resource use and annual direct medical costs during the year of mortality and the year preceding the year of mortality (12-24 months before mortality) were analysed by the covariates gender, age group, presence of comorbidities, presence of diabetic complications (heart disease, stroke, diabetic nephropathy or diabetic retinopathy), and primary cause of death.
Generalized linear models with an identity-link function and loglink function with gamma distribution were used to explore the associations of the annual direct medical costs. Both the log-link function and identify-link function in the generalized linear model were used for estimations of direct medical costs, in line with a previous costing study. 8 
| Costs in the mortality year and years before mortality
Annual direct medical costs, their 95% CIs and the proportion of the cost of hospitalization of patients with DM in the mortality year and the years before mortality are presented in Figure 1 . The closer the mortality year, the higher the annual direct medical costs and the higher the proportions of the hospitalization cost over the annual direct medical cost. The average medical cost doubled from US $11807 (73.7% for hospitalization cost) in the year preceding the year of mortality to US$22987.50 (78.4% for hospitalization cost) in the year of mortality (Figure 1 ). Because the costs in the 48 to 60 months before mortality, the 36 to 48 months before mortality and the 24 to 36 months before mortality were roughly similar, while the costs in the 12 to 24 months before mortality and in the mortality year were much higher, the detailed results are only presented for the year preceding the year of mortality (12-24 months before death) and the year of mortality.
| Utilization of healthcare services
The frequencies of healthcare services attendance for each patient in Table 1 ). Because the unit costs of hospital stay in the general ward, the intensive care unit and the high dependency unit were at least four times those of the general outpatient clinic and specialist outpatient clinic visits, 9 the annual direct medical cost in the mortality year was higher than that in the year preceding the year of mortality. The medical costs were almost double in the mortality year compared to the preceding year for both men and women (Table 2) .
| Comparison of the annual direct medical cost by time and existence of covariates
Analysed by age group, the group with the highest cost in the year preceding the year of mortality was aged ≥85 years (US $12172.1) and the group with the highest cost for the mortality year was patients aged 65 to 74 years (US$24459.9). The medical costs for all age groups were nearly double in the mortality year (1.94 times for those aged <65 years; 2.27 times for those aged 65-74 years;
1.97 times for those aged 75-84 years; 1.76 times for those aged ≥85 years; Table 2 ).
By ethnicity, higher medical costs were recorded for Chinese patients in both the year preceding the year of mortality and the mortality year (US$11992.6 and US$23216.6 for Chinese patients; US$6394.0 and US$16304.5 for non-Chinese patients, respectively).
The costs in the mortality year in the two groups were doubled compared to the costs in the preceding year (1.94 times for Chinese patients; 2.54 times for non-Chinese patients; Table 2 ).
For type of diabetes, patients with non-insulin-dependent diabetes had significantly higher medical costs in the mortality year than in the preceding year (US$22988.8 vs US$11819.2; P < .001), but insignificantly higher costs for patients with insulin-dependent diabetes in both years (US$23789 vs US$14525.9; P = .1236 [ Table 2] ).
Analysed by comorbidities, the higher the CCI score, the higher the medical cost in the mortality year. The medical cost in the mortality year was 1.5 times greater than in the year preceding the year of mortality, regardless of CCI score (1.96 times for score 0; 1.61 times for score 1; 2.17 times for score 2; 1.84 times for score ≥ 3
[ Table 2 ]).
Patients with at least one diabetes-related complications incurred higher costs than those without both in the year of mortality (US $24585.6 vs US$20358.5) and in the preceding year (US$13509.0 vs US$9007.1). The medical costs in the mortality year were twice as high as the costs in the year preceding the year of mortality (1.82 times for patients with any diabetic complications; 2.26 times for patients without diabetic complication [ Table 2 ]).
The most costly primary cause of death in the year preceding the year of mortality was diseases of the genitourinary system (US $16696.4), whereas the most costly primary cause of death for the mortality year was infectious and parasitic diseases (US$32989.0).
The ratio of the costs in the mortality year to the costs in the year before mortality varied from 1.43 to 3.35 times ( Table 2) .
3.5 | Association between the annual direct medical costs and patients' covariates Tables 3 and 4 show the estimated coefficients of the effect of covariates on direct medical costs of patients with DM using the generalized models with identify link and log link, respectively.
3.5.1 | Fitting a generalized linear model using the identity link with gamma distribution Table 4 shows that the base-case annual average medical cost was US$6172.2 in the year before death (≥85-year-old man without any diabetic complications with "other" primary cause of death). Women with DM had a higher cost than men, with a multiplier of 1.037.
| Fitting a generalized linear model using the log link with gamma distribution
Compared with the patients aged ≥85 years, all the patients in other age groups had higher costs (with multipliers of 1.357, 1.060 and 13 Patients had diagnosis of both insulin-dependent and non-insulin-dependent. b Charlson comorbidities for diabetes with and without chronic complications were excluded from the CCI calculation to avoid double-counting.
the most costly diabetic complication was diabetic foot ulcer (with a multiplier of 1.660). The most costly primary cause of death was infectious and parasitic diseases (with a multiplier of 2.369).
| Goodness-of-fit of models
Both the MAE and RMSE of the generalized linear model using the identity link with gamma distribution were smaller than the generalized linear model using the log link with gamma distribution (year preceding the year of mortality: MAE 13171.4 vs 13 266.8, RMSE 222.9 vs 260.1; mortality year: MAE 17737.8 vs 17 877.9, RMSE 223.8 vs 261.4); therefore, the generalized linear model using the identity link with gamma distribution was preferred over that using the log-link with gamma distribution.
| DISCUSSION
To quantify the burden of DM on healthcare providers, healthcare resource use and annual direct medical costs have been estimated using routine administrative databases in many developed countries such as the United States, 3,11 the United Kingdom, 4,12 Denmark, 13 Australia, 14 Sweden, 15 and Singapore. 16 Nevertheless, the aforementioned studies primarily assessed the impact of diabetes-related complications on healthcare costs while the present study utilized the patient-level data within a hospital administrative database, and reported the robust estimates of annual direct medical costs during the mortality year and the years before mortality. Importantly, annual direct medical costs in the mortality year (US$22,987.5) were almost double those in the preceding year (US$11,807.0), confirming the notion of "the high cost of dying", 17 in that the annual healthcare costs of patients with DM in their last year of life were greater than those of patients with DM who survived. High costs in the mortality year were possibly attributable to the occurrence of diabetes-related complications. Evidence from diabetes models (eg, in the UKPDS 82) 18 showed that patients with DM had a higher probability of death in the first year of a complication event. The healthcare costs of patients for whom complication events occurred in the first year were significantly greater than those of patients without a complica- The costs associated with diabetic foot ulcer in the year of the event and in subsequent years were not derived in most of the costing analyses, 3, 4, 12, 13, 16 whereas diabetic foot ulcer was part of a broad category, peripheral circulatory complications, in one Swedish study. 15 As demonstrated in the present study, however, diabetic foot ulcer was one of the most expensive diabetes-related complications, in line with previous retrospective cohort studies. 8, 11, 14 Furthermore, with regard to the variable primary cause of death, patients with DM who died from infectious and parasitic diseases had the highest incremental annual direct medical costs in the mortality year (US$18218.2). Of those patients whose primary cause of death was in that category, 83.5% died from sepsis.
With regard to healthcare resource use in the public sector, patients with DM had fewer outpatient visits and allied health professional visits in their mortality year than in the year preceding the year of mortality. By contrast, these patients had more emergency visits and hospitalization in general wards and intensive care units in their mortality year than in the year preceding the mortality year. Closer to the mortality year, patients with DM relied on secondary care delivered by hospitals rather than primary care mainly delivered by outpatient clinics. In addition to age and composition of comorbidities, the time-to-death was a determinant of healthcare utilization and direct medical costs in patients with DM, as also shown in a previous study. 7 Hence, the healthcare utilization pattern observed in the present study could help policy-makers to plan healthcare services and allocate resources according to life expectancy and time-to-death information on patients with DM.
Another important finding of the present study was the significant increase in healthcare costs in the mortality year in comparison to those in the preceding year. Differences in accrued health costs between the 2 years provides a strong argument for the refinement of the cost structure in costing and cost-effectiveness analysis of health interventions for DM. Conventionally, cost-effectiveness modelling has assumed that the healthcare costs in patients with DM in Hong Kong are the same over the time horizon, and do not account for the differences in healthcare costs between the mortality and non-mortality years. [19] [20] [21] [22] Evidence from the present study supports the adjustment of direct medical costs in the mortality year and year preceding the year of mortality in future cost-effectiveness analyses.
The present study has some limitations. Firstly, the unit costs of each healthcare service item were obtained from documents published by the Hong Kong Government Gazette, in which no temporal adjustment or inflation was taken into consideration. Each patient was assumed to have the same unit cost for each healthcare service item, which was a packaged price inclusive of consultation, investigations, prescribed medications, radiology and other examinations during the clinic visit or hospital stay. Actual resource use for each healthcare service item, in terms of human resources, equipment, consumables and overheads, were assumed to be the same. As such, the annual direct medical costs in the death year and years before death might be biased, and valid only for Hong Kong patients with DM and for the time period when unit costs of healthcare service are still current. Secondly, the present analysis estimated public healthcare utilization and corresponding annual direct medical costs attributable to patients with DM from a government-based public healthcare provider perspective.
Resource use in the private sector and indirect costs based on productivity losses were not taken into consideration. Finally, the cause of healthcare resource use is an important issue for consideration. Especially for elderly patients with DM, a proportion of healthcare resource use and costs might be unrelated to DM or diabetes-related complications However, it was not possible using our retrospective cohort data to differentiate the causes of the healthcare resource use or to determine whether the healthcare resource use was attributable to primary cause of death or diabetic complications.
In conclusion, the annual direct medical costs of patients with DM in the mortality year were almost twice as high as those in the preceding year. Healthcare costs in both the mortality year and the preceding year were influenced by the presence of diabetes-related complications and primary cause of death. This analysis provides new evidence to support incorporating an additional direct medical cost in the mortality year and refining the structure of total cost estimates for use in costing and costeffectiveness analyses of health interventions for DM.
